A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for Ovarian Cancer
30 locations incl. Birmingham
Sponsor: Merck Sharp & Dohme LLC
Sex: Female·Age: 18+
Code: NCT06824467·Phase 3·Recruiting